



Vyteris Announces Launch of Initiative to Pursue Joint Development Agreements in Pain Management

Potential Candidate Drugs Identified for Use with Transdermal Drug Delivery System

FAIR LAWN, N.J., Aug 05, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTC BB: VYTR), manufacturer of the first U.S. Food and Drug Administration (FDA)-approved active patch transdermal drug delivery system, announced an initiative to identify and target candidate drugs in the pain management field that could potentially be delivered using Vyteris' active patch transdermal system.

"Our first successful FDA approval for our active patch transdermal system was for topical delivery of lidocaine, and we are now examining other drugs in pain management for use in our system as the next step in our market development," said Haro Hartounian, Ph D., president of Vyteris, Inc. "We believe the unique properties of several pain medications make them excellent candidates for testing and use with our system. We have proven the concept of transdermal delivery of pain medication using our system - now we are looking to demonstrate that our system is versatile and can work with a variety of different drugs in the pain management area."

Vyteris' Pain Management Initiative will examine several candidate drugs to improve their safety and efficacy profiles using Vyteris's proprietary controlled drug delivery technology and to potentially extend their patent protection. The initiative will include efforts to secure joint development agreements with pharmaceutical manufacturers for in vitro and in vivo testing of pain medication compounds.

Compounds under investigation for possible use include NSAIDs, opioids, narcotic analgesics and anaesthetic agents. In contrast to other transdermal drug delivery technologies being developed, iontophoresis is a well established technology that is unique in its ability to control the flux of drug through the skin for either topical or systemic drug delivery applications.

Vyteris is currently in Phase I testing of transdermal delivery of a peptide molecule for use in treating female fertility as part of a joint development agreement with Ferring Pharmaceuticals and has already demonstrated successful delivery of a peptide.

About Vyteris, Inc.

Vyteris, Inc. is the maker of the first active drug delivery patch to receive marketing clearance from the FDA. Vyteris' proprietary active transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. Companies interested in our technology can call (201) 703-2299. For more information, please visit us at www.vyteris.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "anticipate," "intend," "plan," "may," "will," "could," "would," "should," "believes," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, statements concerning the potential impact of other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others, the competitive environment. The Company has described other important risks and uncertainties under the caption "Risk Factors" in its most recent Annual Report on Form 10-KSB and in various filings made with the SEC. Actual results may differ materially from those contained in the forward-looking statements in this press release.

To receive regular email updates, please click (http://www.vyteris.com/home/Contact_Us/index.php)

To watch a video on how our technology works, please click (http://www.vyteris.com/home/Our_Technology/MOA.php)

SOURCE: Vyteris, Inc.

The Lee Strategy Group, Inc.

James Lee, 310-229-5771

jlee@leestategy.com

or

CEOcast, Inc.

Gary Nash, 212-732-4300

gnash@ceocast.com

Copyright Business Wire 2008

News Provided by COMTEX